AstraZeneca divestment of Movantik to RedHill Biopharma completed Medical Dialogues Bureau4 April 2020 5:30 AMUK: AstraZeneca has completed the previously communicated agreement to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada,...
AstraZeneca to sublicense global rights to Movantik Medical Dialogues Bureau28 Feb 2020 3:30 AMMovantik is a once-daily oral PAMORA approved by the US Food and Drug Administration for the treatment of OIC in adult patients with chronic...